Literature DB >> 20230549

Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?

Eleanor M Pullenayegum1, Jean-Eric Tarride, Feng Xie, Ron Goeree, Hertzel C Gerstein, Daria O'Reilly.   

Abstract

BACKGROUND: Health utility data often show an apparent truncation effect, where a proportion of individuals achieve the upper bound of 1. The Tobit model and censored least absolute deviations (CLAD) have both been used as analytic solutions to this apparent truncation effect. These models assume that the observed utilities are censored at 1, and hence that the true utility can be greater than 1.We aimed to examine whether the Tobit and CLAD models yielded acceptable results when this censoring assumption was not appropriate.
METHODS: Using health utility (captured through EQ5D) data from a diabetes study, we conducted a simulation to compare the performance of the Tobit, CLAD, ordinary least squares (OLS), two-part and latent class estimators in terms of their bias and estimated confidence intervals. We also illustrate the performance of semiparametric and nonparametric bootstrap methods.
RESULTS: When the true utility was conceptually bounded above at 1, the Tobit and CLAD estimators were both biased. The OLS estimator was asymptotically unbiased and, while the model-based and semiparametric bootstrap confidence intervals were too narrow, confidence intervals based on the robust standard errors or the nonparametric bootstrap were acceptable for sample sizes of 100 and larger. Two-part and latent class models also yielded unbiased estimates.
CONCLUSIONS: When the intention of the analysis is to inform an economic evaluation, and the utilities should be bounded above at 1, CLAD, and Tobit methods were biased. OLS coupled with robust standard errors or the nonparametric bootstrap is recommended as a simple and valid approach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20230549     DOI: 10.1111/j.1524-4733.2010.00695.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  56 in total

1.  Improving the mapping of condition-specific health-related quality of life onto SF-6D score.

Authors:  Yingsi Yang; M Y Wong; Cindy L K Lam; Carlos K H Wong
Journal:  Qual Life Res       Date:  2014-03-29       Impact factor: 4.147

2.  Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.

Authors:  Azin Nahvijou; Hossein Safari; Mahmood Yousefi; Marziyeh Rajabi; Morteza Arab-Zozani; Hosein Ameri
Journal:  Breast Cancer       Date:  2020-07-25       Impact factor: 4.239

3.  Regression estimators for generic health-related quality of life and quality-adjusted life years.

Authors:  Anirban Basu; Andrea Manca
Journal:  Med Decis Making       Date:  2011-10-18       Impact factor: 2.583

4.  A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017.

Authors:  Ashley S Cha; Ernest H Law; James W Shaw; A Simon Pickard
Journal:  Qual Life Res       Date:  2019-07-18       Impact factor: 4.147

5.  Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.

Authors:  Mónica Hernández Alava; Allan Wailoo; Stephen Pudney; Laura Gray; Andrea Manca
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

6.  Exclusion Criteria as Measurements II: Effects on Utility Functions.

Authors:  Barry Dewitt; Baruch Fischhoff; Alexander L Davis; Stephen B Broomell; Mark S Roberts; Janel Hanmer
Journal:  Med Decis Making       Date:  2019-08-28       Impact factor: 2.583

7.  Short term health-related quality of life improvement during opioid agonist treatment.

Authors:  B Nosyk; J W Bray; E Wittenberg; B Aden; A A Eggman; R D Weiss; J Potter; A Ang; Y-I Hser; W Ling; B R Schackman
Journal:  Drug Alcohol Depend       Date:  2015-10-25       Impact factor: 4.492

8.  Association between glycated hemoglobin and health utility for Type 1 diabetes.

Authors:  R Brett McQueen; Samuel L Ellis; David M Maahs; Heather D Anderson; Kavita V Nair; Anne M Libby; Jonathan D Campbell
Journal:  Patient       Date:  2014       Impact factor: 3.883

9.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

10.  Mapping EQ-5D utility scores from the PedsQL™ generic core scales.

Authors:  Kamran A Khan; Stavros Petrou; Oliver Rivero-Arias; Stephen J Walters; Spencer E Boyle
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.